Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

Publications

Recent publications published by researchers at the MRC WIMM.

The impact of viral mutations on recognition by SARS-CoV-2 specific T-cells

DONG T. et al, (2021), BioRxiv

T cell assays differentiate clinical and subclinical SARS-CoV-2 infections from cross-reactive antiviral responses.

Ogbe A. et al, (2021), Nat Commun, 12

Antibody evasion by the P.1 strain of SARS-CoV-2.

Dejnirattisai W. et al, (2021), Cell

Characterization of humoral and SARS-CoV-2 specific T cell responses in people living with HIV.

Alrubayyi A. et al, (2021), Res Sq

Single-dose administration and the influence of the timing of the booster dose on immunogenicity and efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine: a pooled analysis of four randomised trials.

Voysey M. et al, (2021), Lancet, 397, 881 - 891

Evidence of escape of SARS-CoV-2 variant B.1.351 from natural and vaccine-induced sera.

Zhou D. et al, (2021), Cell

The antigenic anatomy of SARS-CoV-2 receptor binding domain

GUPTA S. et al, (2021), Cell

Reduced neutralization of SARS-CoV-2 B.1.1.7 variant by convalescent and vaccine sera.

Supasa P. et al, (2021), Cell

Characterization of humoral and SARS-CoV-2 specific T cell responses in people living with HIV.

Alrubayyi A. et al, (2021), bioRxiv

Promises and challenges of adoptive T-cell therapies for solid tumours

AHMED A. et al, (2021), British Journal of Cancer

Phase 1/2 trial of SARS-CoV-2 vaccine ChAdOx1 nCoV-19 with a booster dose induces multifunctional antibody responses.

Barrett JR. et al, (2020), Nat Med

T cell and antibody responses induced by a single dose of ChAdOx1 nCoV-19 (AZD1222) vaccine in a phase 1/2 clinical trial.

Ewer KJ. et al, (2020), Nat Med

Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK.

Voysey M. et al, (2020), Lancet

Clinical perspective and practices on pleural effusions in chronic systemic inflammatory diseases.

Yao X. et al, (2020), Breathe (Sheff), 16

Performance characteristics of five immunoassays for SARS-CoV-2: a head-to-head benchmark comparison.

National SARS-CoV-2 Serology Assay Evaluation Group None., (2020), Lancet Infect Dis, 20, 1390 - 1400

Safety and immunogenicity of ChAdOx1 nCoV-19 vaccine administered in a prime-boost regimen in young and old adults (COV002): a single-blind, randomised, controlled, phase 2/3 trial.

Ramasamy MN. et al, (2020), Lancet

Broad and strong memory CD4+ and CD8+ T cells induced by SARS-CoV-2 in UK convalescent individuals following COVID-19.

Peng Y. et al, (2020), Nat Immunol, 21, 1336 - 1345

IFITM3-specific antibody reveals interferon preferences and slow interferon induction of the anti-viral factor IFITM3 in humans

WELLINGTON D. et al, (2020), European Journal of Immunology

Patient-derived malignant pleural mesothelioma cell cultures: a tool to advance biomarker-driven treatments.

Kanellakis NI. et al, (2020), Thorax

Studying the biological properties of pleural fluid: pleural fluid alone is adequate for cancer cell proliferation in vitro

Asciak R. et al, (2020), EUROPEAN RESPIRATORY JOURNAL, 56

Load More

1
2
3
4
5
6
7
...
»

Include forthcoming?